Sodium channel protein type 9 subunit alpha · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Sodium channel protein type 9 subunit alpha shows late clinical disease relevance led by trigeminal neuralgia. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q15858. Start with trigeminal neuralgia, then reuse UniProt Q15858 as the stable protein anchor across project notes and exports.
Start with trigeminal neuralgia, then reuse UniProt Q15858 as the stable protein anchor across project notes and exports.
Sodium channel protein type 9 subunit alpha shows late clinical disease relevance led by trigeminal neuralgia. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with trigeminal neuralgia because it currently carries late clinical support. Linked drugs include VIXOTRIGINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxySodium channel protein type 9 subunit alpha
Review this target as Sodium channel protein type 9 subunit alpha, mapped to UniProt Q15858. Sequence length is 1988 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Sodium channel protein type 9 subunit alpha as ChEMBL target CHEMBL4296, mapped to UniProt Q15858. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Sodium channel protein type 9 subunit alpha is the right protein anchor across sources, using UniProt Q15858 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why trigeminal neuralgia is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Sodium channel protein type 9 subunit alpha |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | Q15858 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Sodium channel protein type 9 subunit alpha |
| UniProt Accession | Q15858 |
| Component Type | Protein |
| Sequence Length | 1988 aa |
Sodium channel protein type 9 subunit alpha
Review this target as Sodium channel protein type 9 subunit alpha, mapped to UniProt Q15858. Sequence length is 1988 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Sodium channel protein type 9 subunit alpha shows late clinical disease relevance led by trigeminal neuralgia. 5 more disease programs remain visible in the same review block.
Start review with trigeminal neuralgia because it currently carries late clinical support. Linked drugs include VIXOTRIGINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL4217988 | 11.0 | IC50 | 0.01 | Preclinical |
| CHEMBL1224266 | 10.74 | Ki | 0.018 | Preclinical |
| CHEMBL3318148 | 10.38 | IC50 | 0.042 | Preclinical |
| CHEMBL4205773 | 10.0 | IC50 | 0.1 | Preclinical |
| CHEMBL4210135 | 10.0 | IC50 | 0.1 | Preclinical |
| CHEMBL1224265 | 9.96 | Ki | 0.111 | Preclinical |
| CHEMBL4640389 | 9.96 | IC50 | 0.11 | Preclinical |
| CHEMBL4215058 | 9.92 | IC50 | 0.12 | Preclinical |
| CHEMBL5994244 | 9.85 | IC50 | 0.141 | Preclinical |
| CHEMBL5819252 | 9.76 | IC50 | 0.173 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 238 | 4,655 | 6.7 |
| single protein format | 89 | 1,632 | 6.5 |
| assay format | 41 | 2,302 | 6.7 |
| cell membrane format | 5 | 49 | 6.6 |
| organism-based format | 1 | 1 | 6.0 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 7 | 50 | 5.7 |
| assay format | 6 | 96 | 6.2 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 2 | 3 | 5.2 |
| single protein format | 1 | 0 | — |